Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy - PubMed (original) (raw)
. 2008 Nov 25;71(22):1796-803.
doi: 10.1212/01.wnl.0000335941.68602.39. Epub 2008 Oct 29.
M Malinverno, F Gardoni, A Alberici, L Parnetti, E Premi, U Bonuccelli, M Grassi, D Perani, P Calabresi, M Di Luca, A Padovani
Affiliations
- PMID: 18971445
- DOI: 10.1212/01.wnl.0000335941.68602.39
Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy
B Borroni et al. Neurology. 2008.
Abstract
Objective: In CSF, extended (55 kDa) and truncated (33 kDa) tau forms have been previously recognized, and the tau 33 kDa/55 kDa ratio has been found significantly reduced in progressive supranuclear palsy (PSP) vs in other neurodegenerative disorders. The aim of this study was to evaluate the diagnostic value of the CSF tau form ratio as a biomarker of PSP and to correlate the structural anatomic changes as measured by means of voxel-based morphometry (VBM) to CSF tau form ratio decrease.
Methods: A total of 166 subjects were included in the study (21 PSP, 20 corticobasal degeneration syndrome, 44 frontotemporal dementia, 29 Alzheimer disease, 10 Parkinson disease, 15 dementia with Lewy bodies, and 27 individuals without any neurodegenerative disorder). Each patient underwent a standardized clinical and neuropsychological evaluation. In CSF, a semiquantitative immunoprecipitation was developed to evaluate CSF tau 33 kDa/55 kDa ratio. MRI assessment and VBM analysis was carried out.
Results: Tau form ratio was significantly reduced in patients with PSP (0.504 +/- 0.284) when compared to age-matched controls (0.989 +/- 0.343), and to patients with other neurodegenerative conditions (range = 0.899-1.215). The area under the curve (AUC) of the receiver operating characteristic analysis in PSP vs other subgroups ranged from 0.863 to 0.937 (PSP vs others, AUC = 0.897, p < 0.0001). VBM study showed that CSF tau form ratio decrease correlated significantly with brainstem atrophy.
Conclusions: Truncated tau production, which selectively affects brainstem neuron susceptibility, can be considered a specific and reliable marker for PSP. Tau form ratio was the lowest in progressive supranuclear palsy with no overlap with any other neurodegenerative illness.
Comment in
- Early diagnosis of progressive supranuclear palsy: bucking the odds.
Golbe LI. Golbe LI. Neurology. 2008 Nov 25;71(22):1754-5. doi: 10.1212/01.wnl.0000338701.59007.ee. Neurology. 2008. PMID: 19029515 No abstract available.
Similar articles
- Pattern of Tau forms in CSF is altered in progressive supranuclear palsy.
Borroni B, Gardoni F, Parnetti L, Magno L, Malinverno M, Saggese E, Calabresi P, Spillantini MG, Padovani A, Di Luca M. Borroni B, et al. Neurobiol Aging. 2009 Jan;30(1):34-40. doi: 10.1016/j.neurobiolaging.2007.05.009. Epub 2007 Aug 20. Neurobiol Aging. 2009. PMID: 17709155 - A combination of CSF tau ratio and midsaggital midbrain-to-pons atrophy for the early diagnosis of progressive supranuclear palsy.
Borroni B, Malinverno M, Gardoni F, Grassi M, Parnetti L, Agosti C, Alberici A, Premi E, Bonuccelli U, Gasparotti R, Calabresi P, Di Luca M, Padovani A. Borroni B, et al. J Alzheimers Dis. 2010;22(1):195-203. doi: 10.3233/JAD-2010-100333. J Alzheimers Dis. 2010. PMID: 20847421 - α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. Mollenhauer B, et al. Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Lancet Neurol. 2011. PMID: 21317042 - [Corticobasal degeneration and atypical progressive supranuclear palsy: their symptomatology, laboratory examination and differential diagnosis].
Morimatsu M, Negoro K, Mori H. Morimatsu M, et al. Rinsho Shinkeigaku. 2004 Nov;44(11):982-5. Rinsho Shinkeigaku. 2004. PMID: 15651349 Review. Japanese. - Neurodegenerative disorders with extensive tau pathology: a comparative study and review.
Feany MB, Dickson DW. Feany MB, et al. Ann Neurol. 1996 Aug;40(2):139-48. doi: 10.1002/ana.410400204. Ann Neurol. 1996. PMID: 8773594 Review.
Cited by
- Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.
Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JA. Jiménez-Jiménez FJ, et al. Front Cell Neurosci. 2014 Nov 11;8:369. doi: 10.3389/fncel.2014.00369. eCollection 2014. Front Cell Neurosci. 2014. PMID: 25426023 Free PMC article. Review. - Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.
Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, Lee VM, Trojanowski JQ. Irwin DJ, et al. Acta Neuropathol. 2015 Apr;129(4):469-91. doi: 10.1007/s00401-014-1380-1. Epub 2014 Dec 31. Acta Neuropathol. 2015. PMID: 25549971 Free PMC article. - Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions.
Magdalinou N, Lees AJ, Zetterberg H. Magdalinou N, et al. J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1065-75. doi: 10.1136/jnnp-2013-307539. Epub 2014 Apr 1. J Neurol Neurosurg Psychiatry. 2014. PMID: 24691581 Free PMC article. Review. - The tau code.
Avila J. Avila J. Front Aging Neurosci. 2009 Jul 30;1:1. doi: 10.3389/neuro.24.001.2009. eCollection 2009. Front Aging Neurosci. 2009. PMID: 20552052 Free PMC article. - Biomarkers in frontotemporal lobar degenerations--progress and challenges.
Hu WT, Trojanowski JQ, Shaw LM. Hu WT, et al. Prog Neurobiol. 2011 Dec;95(4):636-48. doi: 10.1016/j.pneurobio.2011.04.012. Epub 2011 Apr 30. Prog Neurobiol. 2011. PMID: 21554923 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous